Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA
Authors:
- Jia LiJLJia Li
- Mei LuMLMei Lu
- Christopher L. BowlusCBChristopher L. Bowlus
- Keith LindorKLKeith Lindor
- Carla Rodriguez-WatsonCRCarla Rodriguez-Watson
- Robert J. RomanelliRRRobert J. Romanelli
- Irina V. HallerIHIrina V. Haller
- Heather AndersonHAHeather Anderson
- Jeffrey J. VanWormerJVJeffrey J. VanWormer
- Joseph A. BoscarinoJBJoseph A. Boscarino
- Mark A. SchmidtMSMark A. Schmidt
- 9 September 2021
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (8) , 4170-4180
Abstract
Background Ursodeoxycholic acid (UDCA) remains the first-line therapy for primary biliary cholangitis (PBC); however, inadequate treatment response (ITR) is common. The UK-PBC Consortium developed the modified UDCA Response Score (m-URS) to predict ITR (using alkaline phosphatase [ALP] > 1.67 times the upper limit of normal [*ULN]) at 12 months post-UDCA initiation). Using data from the US-based Fibrotic Liver Disease Consortium, we assessed the m-URS in our multi-racial cohort. We then used a dynamic modeling approach to improve prediction accuracy. Methods Using data collected at the time of UDCA initiation, we assessed the m-URS using the original formula; then, by calibrating coefficients to our data, we also assessed whether it remained accurate when using Paris II criteria for ITR. Next, we developed and validated a dynamic risk prediction model that included post-UDCA initiation laboratory data. Results Among 1578 patients (13% men; 8% African American, 9% Asian American/American Indian/Pacific Islander; 25% Hispanic), the rate of ITR was 27% using ALP > 1.67*ULN and 45% using Paris II criteria. M-URS accuracy was “very good” (AUROC = 0.87, sensitivity = 0.62, and specificity = 0.82) for ALP > 1.67*ULN and “moderate” (AUROC = 0.74, sensitivity = 0.57, and specificity = 0.70) for Paris II. Our dynamic model significantly improved accuracy for both definitions of ITR (ALP > 1.67*ULN: AUROC = 0.91; Paris II: AUROC = 0.81); specificity approached 100%. Roughly 9% of patients in our cohort were at the highest risk of ITR. Conclusions Early identification of patients who will not respond to UDCA treatment using a dynamic prediction model based on longitudinal, repeated risk factor measurements may facilitate earlier introduction of adjuvant treatment.Keywords
Funding Information
- Intercept Pharmaceuticals
This publication has 11 references indexed in Scilit:
- Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary CholangitisClinical Gastroenterology and Hepatology, 2019
- Precision medicine in primary biliary cholangitisJournal of Digestive Diseases, 2019
- Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreThe Lancet Gastroenterology & Hepatology, 2018
- Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With TreatmentClinical Gastroenterology and Hepatology, 2018
- Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health SystemsClinical Gastroenterology and Hepatology, 2018
- Primary biliary cirrhosisThe Lancet, 2015
- Geoepidemiology of primary sclerosing cholangitis: A critical reviewJournal of Autoimmunity, 2013
- Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcomeJournal of Hepatology, 2011
- The AST/ALT ratio as an indicator of cirrhosis in patients with PBCLiver International, 2006
- Multiple Imputation for Nonresponse in Surveys1987